The Cooperative Study Group for Autoimmune Disease Prevention (CSGADP) was established in 2001 as a collaborative network of investigators with a focus on prevention of autoimmune disease, defined as halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression, and an emphasis on Type 1 diabetes. The initial network of five cooperative agreements was funded by NIAID, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institutes of Health (NIH) Office for Research in Women’s Health, and the JDRF. In 2012, the Study Group was renewed through RFA AI11-034 with the award of seven 5-year cooperative agreements.
The mission of the CSGADP is to engage in scientific discovery that significantly advances knowledge for the prevention and regulation of autoimmune disease. The specific goals enunciated in pursuit of this mission are
The current Study Group includes the following cooperative agreements and principal investigators (links are to non-federal websites):
All of these principal investigators sit on the Group’s Steering Committee, with Dr. Buckner serving as Chair. NIH representatives to the Steering Committee include Beena Akolkar (NIDDK) and Thomas Esch (NIAID).
The Steering Committee of the Cooperative Study Group for Autoimmune Disease Prevention (CSGADP) has access to an Infrastructure and Opportunities Fund to support pilot projects of up to $75,000 for 1 year. Projects that are aligned with the mission of the CSGADP to engage in scientific discovery that significantly advances knowledge for the primary prevention and regulation of human autoimmune disease will be given priority. Specific areas of emphasis include
Projects eligible for discretionary fund support should be novel, exciting, high-risk and focused on research into the etiology and immune mechanisms of human autoimmune disease. Projects that employ human systems or materials are preferred, but animal studies that can clearly be translated to human settings will be considered. Pilot proposals should be 1 year in length with a total direct cost budget of up to $75,000.
Applicants must be affiliated with an established research institution and be recognized as independent investigators (eligible to submit an R01 application to NIH) by that institution. Priority will be given to investigators who have not received pilot funding through this mechanism in the past. It is recommended that potential applicants should contact a member of the Steering Committee for guidance and assistance (listed below).
All proposals should include a two-page research plan, NIH biosketch for key personnel, and a proposed budget (inclusive of direct and indirect costs: use of standard NIH budget pages is acceptable). The research plan should include specific aims, a statement of significance in relation to the goal of the CSGADP, innovation, feasibility, research methods, and a proposed timeline. Preliminary data are not required for pilot proposals. Proposals are due September 30, 2015. The grants will be reviewed in mid-October, with funding beginning in November 2015.
PIs of successful proposals will be required to submit the following documents as a part of the Just-in-Time process:
Dr. Paul Bollyky: firstname.lastname@example.org (T1D, matrix immunology)
Dr. Jane Buckner: email@example.com (autoimmunity and immune regulation)
Dr. David Hafler: firstname.lastname@example.org (multiple sclerosis, genetics of autoimmunity)
Dr. Michael Holers: email@example.com (rheumatoid arthritis)
Dr. Judith James: firstname.lastname@example.org (systemic lupus)
Dr. Nora Sarvetnick: email@example.com (T1D)
Dr. Matthias von Herrath: firstname.lastname@example.org (T1D)
To submit your proposal, please email to email@example.com.
Last Updated August 25, 2015